## Simona Capsoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8459750/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Getting Into the Brain: The Intranasal Approach to Enhance the Delivery of Nerve Growth Factor and Its Painless Derivative in Alzheimer's Disease and Down Syndrome. Frontiers in Neuroscience, 2022, 16, 773347.	1.4	5
2	A Microglial Function for the Nerve Growth Factor: Predictions of the Unpredictable. Cells, 2022, 11, 1835.	1.8	3
3	Targeting the Cation-Chloride Co-Transporter NKCC1 to Re-Establish GABAergic Inhibition and an Appropriate Excitatory/Inhibitory Balance in Selective Neuronal Circuits: A Novel Approach for the Treatment of Alzheimer's Disease. Brain Sciences, 2022, 12, 783.	1.1	5
4	Intranasal delivery of BDNF rescues memory deficits in AD11 mice and reduces brain microgliosis. Aging Clinical and Experimental Research, 2021, 33, 1223-1238.	1.4	23
5	Nerve Growth Factor Neutralization Promotes Oligodendrogenesis by Increasing miR-219a-5p Levels. Cells, 2021, 10, 405.	1.8	7
6	Understanding pain perception through genetic painlessness diseases: The role of NGF and proNGF. Pharmacological Research, 2021, 169, 105662.	3.1	9
7	Unraveling the Role of Dopaminergic and Calretinin Interneurons in the Olfactory Bulb. Frontiers in Neural Circuits, 2021, 15, 718221.	1.4	10
8	Involvement of Bradykinin Receptor 2 in Nerve Growth Factor Neuroprotective Activity. Cells, 2020, 9, 2651.	1.8	6
9	The NGF <sup>R100W</sup> Mutation Specifically Impairs Nociception without Affecting Cognitive Performance in a Mouse Model of Hereditary Sensory and Autonomic Neuropathy Type V. Journal of Neuroscience, 2019, 39, 9702-9715.	1.7	18
10	Painless Nerve Growth Factor: A TrkA biased agonist mediating a broad neuroprotection via its actions on microglia cells. Pharmacological Research, 2019, 139, 17-25.	3.1	32
11	Cholinergic striatal neurons are increased in HSAN V homozygous mice despite reduced NCF bioavailability. Biochemical and Biophysical Research Communications, 2019, 509, 763-766.	1.0	6
12	<scp>NGF</scp> steers microglia toward a neuroprotective phenotype. Glia, 2018, 66, 1395-1416.	2.5	72
13	The retina as a window to early dysfunctions of Alzheimer's disease following studies with a 5xFAD mouse model. Neurobiology of Aging, 2018, 67, 181-188.	1.5	51
14	The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor. Brain, 2017, 140, 201-217.	3.7	34
15	ProNGF Drives Localized and Cell Selective Parvalbumin Interneuron and Perineuronal Net Depletion in the Dentate Gyrus of Transgenic Mice. Frontiers in Molecular Neuroscience, 2017, 10, 20.	1.4	10
16	Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a "Painless―Lead Investigational Candidate for Therapeutic Applications. PLoS ONE, 2015, 10, e0136425.	1.1	32
17	From genes to pain: nerve growth factor and hereditary sensory and autonomic neuropathy type V. European Journal of Neuroscience, 2014, 39, 392-400.	1.2	39
18	Neutralization of Nerve Growth Factor Impairs Proliferation and Differentiation of Adult Neural Progenitors in the Subventricular Zone. Stem Cells, 2014, 32, 2516-2528.	1.4	30

SIMONA CAPSONI

#	Article	IF	CITATIONS
19	Amyloid Plaque-Independent Deficit of Early Postnatal Visual Cortical Plasticity in the 5XFAD Transgenic Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 103-107.	1.2	10
20	The positional identity of mouse ES cell-generated neurons is affected by BMP signaling. Cellular and Molecular Life Sciences, 2013, 70, 1095-1111.	2.4	29
21	Dissecting the role of sortilin receptor signaling in neurodegeneration induced by NGF deprivation. Biochemical and Biophysical Research Communications, 2013, 431, 579-585.	1.0	22
22	Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1935-1940.	3.3	41
23	Pathogen-Free Husbandry Conditions Alleviate Behavioral Deficits and Neurodegeneration in AD10 Anti-NGF Mice. Journal of Alzheimer's Disease, 2013, 38, 951-964.	1.2	3
24	Nerve growth factor regulates axial rotation during early stages of chick embryo development. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2009-2014.	3.3	36
25	SorLA Deficiency Dissects Amyloid Pathology from Tau and Cholinergic Neurodegeneration in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 357-371.	1.2	13
26	Interaction between NH2-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration. Neurobiology of Aging, 2012, 33, 833.e1-833.e25.	1.5	78
27	Intranasal "painless―Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1 Mice. PLoS ONE, 2012, 7, e37555.	1.1	60
28	Pathogen Free Conditions Slow the Onset of Neurodegeneration in a Mouse Model of Nerve Growth Factor Deprivation. Journal of Alzheimer's Disease, 2012, 31, 1-6.	1.2	21
29	Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opinion on Drug Delivery, 2011, 8, 1277-1296.	2.4	57
30	Gene Expression Biomarkers in the Brain of a Mouse Model for Alzheimer's Disease: Mining of Microarray Data by Logic Classification and Feature Selection. Journal of Alzheimer's Disease, 2011, 24, 721-738.	1.2	104
31	Early inflammation and immune response mRNAs in the brain of AD11 anti-NGF mice. Neurobiology of Aging, 2011, 32, 1007-1022.	1.5	23
32	Taking Pain Out of NGF: A "Painless―NGF Mutant, Linked to Hereditary Sensory Autonomic Neuropathy Type V, with Full Neurotrophic Activity. PLoS ONE, 2011, 6, e17321.	1.1	84
33	Chapter 17. A New Generation of Noninvasive NGF-Based Therapies for Alzheimer's Disease. RSC Drug Discovery Series, 2010, , 43-77.	0.2	1
34	Peripheral Neutralization of Nerve Growth Factor Induces Immunosympathectomy and Central Neurodegeneration in Transgenic Mice. Journal of Alzheimer's Disease, 2010, 20, 527-546.	1.2	77
35	Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12299-12304.	3.3	73
36	In the Adult Hippocampus, Chronic Nerve Growth Factor Deprivation Shifts GABAergic Signaling from the Hyperpolarizing to the Depolarizing Direction. Journal of Neuroscience, 2010, 30, 885-893.	1.7	49

SIMONA CAPSONI

#	Article	IF	CITATIONS
37	In vitro receptor binding properties of a "painless―NGF mutein, linked to hereditary sensory autonomic neuropathy type V. Biochemical and Biophysical Research Communications, 2010, 391, 824-829.	1.0	47
38	Transgenic Mice with Chronic NGF Deprivation and Alzheimer's Disease-Like Pathology Display Hippocampal Region-Specific Impairments in Short- and Long-Term Plasticities. Journal of Neuroscience, 2010, 30, 13089-13094.	1.7	45
39	Aβ-Dependent Inhibition of LTP in Different Intracortical Circuits of the Visual Cortex: The Role of RAGE. Journal of Alzheimer's Disease, 2009, 17, 59-68.	1.2	50
40	Development of a Non Invasive NGF-Based Therapy for Alzheimers Disease. Current Alzheimer Research, 2009, 6, 158-170.	0.7	83
41	Delivery of NGF to the Brain: Intranasal versus Ocular Administration in Anti-NGF Transgenic Mice. Journal of Alzheimer's Disease, 2009, 16, 371-388.	1.2	52
42	Receptor for Advanced Glycation End Product-Dependent Activation of p38 Mitogen-Activated Protein Kinase Contributes to Amyloid-Î <sup>2</sup> -Mediated Cortical Synaptic Dysfunction. Journal of Neuroscience, 2008, 28, 3521-3530.	1.7	189
43	Towards Non Invasive Nerve Growth Factor Therapies for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 255-283.	1.2	87
44	Environmental Enrichment Delays the Onset of Memory Deficits and Reduces Neuropathological Hallmarks in a Mouse Model of Alzheimer-Like Neurodegeneration. Journal of Alzheimer's Disease, 2007, 11, 359-370.	1.2	100
45	A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease. Angewandte Chemie - International Edition, 2007, 46, 3689-3692.	7.2	172
46	Time window in cholinomimetic ability to rescue long-term potentiation in neurodegenerating anti-nerve growth factor mice. Journal of Alzheimer's Disease, 2006, 9, 59-68.	1.2	18
47	Failure of nicotine-dependent enhancement of synaptic efficacy at Schaffer-collateral CA1 synapses of AD11 anti-nerve growth factor transgenic mice. European Journal of Neuroscience, 2006, 24, 1252-1264.	1.2	27
48	On the Molecular Basis Linking Nerve Growth Factor (NGF) to Alzheimer's Disease. Cellular and Molecular Neurobiology, 2006, 26, 617-631.	1.7	98
49	Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3811-3816.	3.3	279
50	Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice. American Journal of Alzheimer's Disease and Other Dementias, 2004, 19, 153-160.	0.9	22
51	Postnatal development of GFAP in mouse visual cortex is not affected by light deprivation. Glia, 2003, 41, 404-414.	2.5	12
52	Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12432-12437.	3.3	204
53	β-Amyloid Plaques in a Model for Sporadic Alzheimer's Disease Based on Transgenic Anti-Nerve Growth Factor Antibodies. Molecular and Cellular Neurosciences, 2002, 21, 15-28.	1.0	95
54	Acute cholinergic rescue of synaptic plasticity in the neurodegenerating cortex of anti-nerve-growth-factor mice. European Journal of Neuroscience, 2002, 15, 1030-1036.	1.2	48

SIMONA CAPSONI

#	Article	IF	CITATIONS
55	Mismatch between BDNF mRNA and protein expression in the developing visual cortex: the role of visual experience. European Journal of Neuroscience, 2001, 13, 709-721.	1.2	55
56	Muscular dystrophy in adult and aged anti-NGF transgenic mice resembles an inclusion body myopathy. , 2000, 59, 553-560.		33
57	Phenotypic Knockout of Nerve Growth Factor in Adult Transgenic Mice Reveals Severe Deficits in Basal Forebrain Cholinergic Neurons, Cell Death in the Spleen, and Skeletal Muscle Dystrophy. Journal of Neuroscience, 2000, 20, 2589-2601.	1.7	206
58	Functional Blockade of Tyrosine Kinase A in the Rat Basal Forebrain by a Novel Antagonistic Anti-Receptor Monoclonal Antibody. Journal of Neuroscience, 1999, 19, 9687-9697.	1.7	48
59	Expression of the melatonin receptor in Xenopus laevis: A comparative study between protein and mRNA distribution. Journal of Pineal Research, 1996, 20, 57-64.	3.4	12
60	Distribution and characterization of the melatonin receptors in the hypothalamus and pituitary gland of three domestic ungulates. Journal of Pineal Research, 1995, 18, 207-216.	3.4	17
61	A carnivore species (Canis familiaris) expresses circadian melatonin rhythm in the peripheral blood and melatonin receptors in the brain. European Journal of Endocrinology, 1994, 131, 191-200.	1.9	15
62	Distribution and characterization of melatonin receptors in the brain of the Japanese quail, Coturnix japonica. Neuroscience Letters, 1993, 150, 149-152.	1.0	52
63	Localization and characterization of melatonin binding sites in the brain of the rabbit (Oryctolagus) Tj ETQq1 1 68-72.	).784314 1.0	rgBT /Overloo 43
64	Vasoactive Intestinal Peptide-Like Immunoreactive Nerve Fibers in the Pineal Gland of the Sheep. Journal of Pineal Research, 1990, 8, 41-47.	3.4	18